211 related articles for article (PubMed ID: 18827609)
1. Should patient-rated performance status affect treatment decisions in advanced lung cancer?
Dajczman E; Kasymjanova G; Kreisman H; Swinton N; Pepe C; Small D
J Thorac Oncol; 2008 Oct; 3(10):1133-6. PubMed ID: 18827609
[TBL] [Abstract][Full Text] [Related]
2. Intrapleural staphylococcal superantigen induces resolution of malignant pleural effusions and a survival benefit in non-small cell lung cancer.
Ren S; Terman DS; Bohach G; Silvers A; Hansen C; Colt H; Sahn SA
Chest; 2004 Nov; 126(5):1529-39. PubMed ID: 15539723
[TBL] [Abstract][Full Text] [Related]
3. Restrictive eligibility limits access to newer therapies in non-small-cell lung cancer: the implications of Eastern Cooperative Oncology Group 4599.
Somer RA; Sherman E; Langer CJ
Clin Lung Cancer; 2008 Mar; 9(2):102-5. PubMed ID: 18501096
[TBL] [Abstract][Full Text] [Related]
4. Baseline quality of life and performance status as prognostic factors in patients with extensive-stage disease small cell lung cancer treated with pemetrexed plus carboplatin vs. etoposide plus carboplatin.
Reck M; Thatcher N; Smit EF; Lorigan P; Szutowicz-Zielinska E; Liepa AM; Winfree KB; Peterson P; Guba SC; Socinski MA
Lung Cancer; 2012 Dec; 78(3):276-81. PubMed ID: 23043970
[TBL] [Abstract][Full Text] [Related]
5. Phase 2 study of concurrent cetuximab plus definitive thoracic radiation therapy followed by consolidation docetaxel plus cetuximab in poor prognosis or elderly patients with locally advanced non-small cell lung cancer.
Dilling TJ; Extermann M; Kim J; Thompson LM; Yue B; Stevens CW; Antonia S; Gray J; Williams C; Haura E; Pinder-Schenck M; Tanvetyanon T; Kim S; Chiappori A
Int J Radiat Oncol Biol Phys; 2014 Nov; 90(4):828-33. PubMed ID: 25216856
[TBL] [Abstract][Full Text] [Related]
6. Association of Performance Status With Survival in Patients With Advanced Non-Small Cell Lung Cancer Treated With Pembrolizumab Monotherapy.
Sehgal K; Gill RR; Widick P; Bindal P; McDonald DC; Shea M; Rangachari D; Costa DB
JAMA Netw Open; 2021 Feb; 4(2):e2037120. PubMed ID: 33570575
[TBL] [Abstract][Full Text] [Related]
7. Prognostic value of performance status assessed by patients themselves, nurses, and oncologists in advanced non-small cell lung cancer.
Ando M; Ando Y; Hasegawa Y; Shimokata K; Minami H; Wakai K; Ohno Y; Sakai S
Br J Cancer; 2001 Nov; 85(11):1634-9. PubMed ID: 11742480
[TBL] [Abstract][Full Text] [Related]
8. A phase II study of docetaxel and carboplatin in Thai patients with advanced non-small-cell lung cancer.
Thongprasert S; Soorraritchingchai S; Chewaskulyong B; Charoentum C; Munprakan S
J Med Assoc Thai; 2006 Feb; 89(2):152-9. PubMed ID: 16579000
[TBL] [Abstract][Full Text] [Related]
9. Randomized phase III trial of single-agent pemetrexed versus carboplatin and pemetrexed in patients with advanced non-small-cell lung cancer and Eastern Cooperative Oncology Group performance status of 2.
Zukin M; Barrios CH; Pereira JR; Ribeiro Rde A; Beato CA; do Nascimento YN; Murad A; Franke FA; Precivale M; Araujo LH; Baldotto CS; Vieira FM; Small IA; Ferreira CG; Lilenbaum RC
J Clin Oncol; 2013 Aug; 31(23):2849-53. PubMed ID: 23775961
[TBL] [Abstract][Full Text] [Related]
10. Prognostic significance of C-reactive protein and smoking in patients with advanced non-small cell lung cancer treated with first-line palliative chemotherapy.
Koch A; Fohlin H; Sörenson S
J Thorac Oncol; 2009 Mar; 4(3):326-32. PubMed ID: 19155996
[TBL] [Abstract][Full Text] [Related]
11. Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial.
Paz-Ares L; de Marinis F; Dediu M; Thomas M; Pujol JL; Bidoli P; Molinier O; Sahoo TP; Laack E; Reck M; Corral J; Melemed S; John W; Chouaki N; Zimmermann AH; Visseren-Grul C; Gridelli C
Lancet Oncol; 2012 Mar; 13(3):247-55. PubMed ID: 22341744
[TBL] [Abstract][Full Text] [Related]
12. Maintenance chemotherapy in advanced NSCLC: a population-based assessment of eligibility.
Tong KM; Laskin J; Ho C
Lung Cancer; 2015 Mar; 87(3):296-302. PubMed ID: 25601487
[TBL] [Abstract][Full Text] [Related]
13. Is fourth-line chemotherapy routine practice in advanced non-small cell lung cancer?
Choi YW; Ahn MS; Jeong GS; Lee HW; Jeong SH; Kang SY; Park JS; Choi JH; Lee SY
Lung Cancer; 2015 Feb; 87(2):155-61. PubMed ID: 25488862
[TBL] [Abstract][Full Text] [Related]
14. Prognostic factors in patients with advanced non-small cell lung cancer: data from the phase III FLEX study.
Pirker R; Pereira JR; Szczesna A; von Pawel J; Krzakowski M; Ramlau R; Vynnychenko I; Park K; Eberhardt WE; de Marinis F; Heeger S; Goddemeier T; O'Byrne KJ; Gatzemeier U
Lung Cancer; 2012 Aug; 77(2):376-82. PubMed ID: 22498112
[TBL] [Abstract][Full Text] [Related]
15. The Functionality Assessment Flowchart (FAF): a new simple and reliable method to measure performance status with a high percentage of agreement between observers.
Paiva CE; Siquelli FA; Santos HA; Costa MM; Massaro DR; Lacerda DC; Nunes JS; de Pádua Souza C; Paiva BS
BMC Cancer; 2015 Jul; 15():501. PubMed ID: 26142726
[TBL] [Abstract][Full Text] [Related]
16. Post-chemotherapy gross tumor volume is predictive of survival in patients with stage III non-small cell lung cancer treated with combined modality therapy.
Stinchcombe TE; Morris DE; Moore DT; Bechtel JH; Halle JS; Mears A; Deschesne K; Rosenman JG; Socinski MA
Lung Cancer; 2006 Apr; 52(1):67-74. PubMed ID: 16499996
[TBL] [Abstract][Full Text] [Related]
17. Survival Analysis of Advanced Non-Small Cell Lung Cancer Patients Treated by Using Wheel Balance Cancer Therapy.
Kim J; Cho CK; Yoo HS
Integr Cancer Ther; 2016 Dec; 15(4):467-477. PubMed ID: 27151594
[TBL] [Abstract][Full Text] [Related]
18. Clinical outcomes of leptomeningeal metastasis in patients with non-small cell lung cancer in the modern chemotherapy era.
Park JH; Kim YJ; Lee JO; Lee KW; Kim JH; Bang SM; Chung JH; Kim JS; Lee JS
Lung Cancer; 2012 Jun; 76(3):387-92. PubMed ID: 22186628
[TBL] [Abstract][Full Text] [Related]
19. Pembrolizumab for advanced nonsmall cell lung cancer: Efficacy and safety in everyday clinical practice.
Ksienski D; Wai ES; Croteau N; Freeman AT; Chan A; Fiorino L; Brooks EG; Poonja Z; Fenton D; Geller G; Irons S; Lesperance M
Lung Cancer; 2019 Jul; 133():110-116. PubMed ID: 31200816
[TBL] [Abstract][Full Text] [Related]
20. Management of advanced non-small-cell lung cancer in patients with a performance status of 2.
Lilenbaum R
Clin Lung Cancer; 2004 Jan; 5(4):209-13. PubMed ID: 14967072
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]